

November 11, 2022

To
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400 023
Fax No.2272 5092/3030

Scrip No. 539680

Sub: Outcome of Board Meeting held on Friday, November 11, 2022

With reference to the captioned subject and in compliance with the regulation 30 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of Company at its meeting held on Friday, November 11, 2022 (commenced at 11.40 a.m. and concluded at 12.15 p.m.) inter alia have considered and approved the un-audited Financial Results of the Company for the half year ended on September 30, 2022.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2022 and limited review report of the Auditors thereon is attached herewith for your perusal.

Please acknowledge and take the same on your records.

Thanking You,

Yours faithfully,

For Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director & CEO
DIN No.: 00077026
Email Id: bharat.sharma@gangapharma.in





Independent Auditors' Review Report on the Standalone half yearly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF GANGA PHARMACEUTICALS LIMITED

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Ganga Pharmaceuticals Limited ("the company") for the half year ended September 30, 2022 ("the statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountant of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Banka & Banka
Chartered Accountants
Firm Registration No. 100979W

PRADEEP Digitally signed by
PRADEEP
PARMESHW PARMESHWAR BANKA
AR BANKA Date: 2022.11.11
11:11:29 +05'30'

Pradeep P Banka
Partner
Membership No.: 038800
Place - Mumbai
Date - November 11, 2022
UDIN - 22038800BCUFMU9134

Statement of Un-Audited Financial Results for the Half and Year ended 30 September,2022

Sr. No	Particulars	Rs.in Lacs				
		Figures for the half year ended on			Financial year ended on	Financial year ended on
		30-09-2022 (Un-Audited)	31-03-2022 (Audited)	30-09-2021 (Un-Audited)	31-03-2022 (Audited)	31-03-2021 (Audited)
1	INCOME FROM OPERATIONS					
	(a) Revenue from operations	135.16	124.39	124.51	248.90	237.44
	(b) Other Income	12.04	15.31	10.55	25.86	25.43
	Total Income	147.19	139.70	135.06	274.76	262.86
2	Expenses					
	(a) Cost of Materials consumed	61.98	79.39	49.04	128.43	142.14
	(b) Purchase of stock in trade					
	(c) Change in inventories of finished goods & packing Material	(0.02)	(10.55)	9.74	(0.81)	(18.48)
	(d) Employee Benefit Expenses	25.69	18.35	25.32	43.47	42.81
	(e) Finance Cost	12.39	9.37	10.11	19.47	19.42
	(f) Depreciation and Amortization Expense	2.78	2.76	2.72	5.48	5.37
	(g) Other Administrative Expenses	40.09	35.91	37.69	73.60	67.86
	Total Expenses	142.92	135.23	134.41	269.64	259.12
3	Profit/(Loss) before Tax (1-2)	4.28	4.47	0.65	5.12	3.74
4	Tax Expenses					
	(a) Current Tax	1.24	0.95	0.41	1.35	0.83
	(b) Deferred Tax	(0.12)	0.22	(0.24)	(0.02)	0.14
	(C) Earlier tax	-	-	-	-	0.73
5	Net Profit / (Loss) for the period (3-4)	3.16	3.31	0.48	3.79	2.04
6	Other Comprehensive Income					
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	406.15	406.15	406.15	406.15	406.15
8	Earning per equity share (Rs.)					
	(1) Basic	0.08	0.08	0.01	0.09	0.05
	(2) Diluted	0.08	0.08	0.01	0.09	0.05

Note

- The above results for the half year ended 30-09-2022 have been reviewed by the Audit Committee in their meeting held on 11th Nov 2022 and approved by the Board of Directors in their meeting held on November 11, 2022.
- The Financial Results of the company have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- Revenues from Operations is net of trade Discounts/ Trade incentives.
- In accordance with AS 17 on 'Operating Segments', the company operated in one business segment viz. Ayurveda Business and hence segment information is not required to be furnished.
- Figures of the corresponding previous period have been regrouped/rearranged wherever necessary to confirm to the classification of the current period.

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bhaskar Sharma
Managing Director & CEO
DIN : 00077026



Place: Virar, Palghar
Date : November 11, 2022

GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305.
Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Un-Audited Assets and Liabilities as at 30th September, 2022

		Rs. in Lacs	
	Particulars	As at (30-09-2022)	As at (31-03-2022)
A	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	406.15	406.15
	(b) Reserve & Surplus	138.09	134.93
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	87.97	89.17
	(b) Deferred Tax Liabilities (Net)	0.57	0.69
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities		
	(a) Short-term borrowings	99.95	92.01
	(b) Trade payables		
	i) Total outstanding dues of micro enterprises and small enterprises	16.38	16.14
	ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	50.19	36.42
	(c) Other current liabilities	11.71	22.64
	(d) Short-term provisions	2.59	1.35
	Total	813.61	799.50
B	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	65.53	68.08
	(b) Non-current investments	8.50	8.50
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	224.92	232.11
	(2) Current assets		
	(a) Current Investment	-	-
	(b) Inventories	113.56	114.99
	(c) Trade receivables	106.12	89.18
	(d) Cash and cash equivalents	1.96	2.04
	(e) Short-term loans and advances	137.37	158.70
	(f) Other current assets	155.64	125.89
	Total	813.61	799.50

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director & CEO
DIN : 00077026



Place : Virar, Palghar
Date : November 11, 2022

GANGA PHARMACEUTICALS LIMITED

Cash Flow Statement for the period Ended 30 Septembeer 2022

	For the Half year ended	For the Half year ended	For the year ended	(Rs.in Lacs) For the year ended
	30th September 2022	30th September 2022	31st March 2022	31st March 2022
	Rupees	Rupees	Rupees	Rupees
A. Cash flow from operating activities:				
Net profit before tax as per Profit and Loss Account.		4.28		5.12
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	2.78		5.48	
Interest on advance & deposit recd	(12.04)		(25.86)	
Finance cost	12.39		19.03	
Prior period item	-		-	
		3.13		(1.35)
Operating profit before working capital changes		7.41		3.77
Movements in working capital:				
(Decrease) / Increase in trade payables	14.02		8.51	
(Decrease) / Increase in other liabilities	(10.93)		(4.63)	
(Decrease) / Increase in Short term borrowing	7.94		3.54	
(Decrease) / Increase in Short term Provision	1.24		0.53	
(Increase) / Decrease in trade receivables	(16.94)		(7.21)	
(Increase) / Decrease in other current assets	(29.75)		(10.25)	
(Increase) / Decrease in Short-term loans and advances	21.33		(12.28)	
(Increase) / Decrease in Inventories	1.43		(1.71)	
		(11.66)		(23.49)
Cash generated from operations		(4.25)		(19.72)
Taxes paid		(1.24)		(1.35)
Net cash from operating activities		(5.49)		(21.07)
B. Cash flow from investing activities:				
Purchase of fixed assets	(0.23)		(1.47)	
Advances given	-		-	
Deposit made / matured during the year	7.19		(5.89)	
Investment made during the year	-		0.43	
Interest received	12.04		25.86	
Net cash used in investing activities		19.00		18.93



 GANGA PHARMACEUTICALS LIMITED
 MUMBAI

GANGA PHARMACEUTICALS LIMITED

Cash Flow Statement (Contd.)

	For the Half year ended	For the Half year ended	For the year ended	For the year ended
	30th September 2022	30th September 2022	31st March 2022	31st March 2022
	Rupees	Rupees	Rupees	Rupees
C. Cash flow from financing activities:				
Repayment of borrowings	(1.20)		21.77	
Proceeds from borrowings	-		-	
Finance cost	(12.39)		(19.03)	
Net cash used in financing activities		(13.59)		2.73
Net increase / (Decrease) in cash and cash equivalents		(0.08)		0.59
Cash and cash equivalents as at the beginning of the year		2.04		1.45
Cash and cash equivalents as at the end of the year		1.96		2.04
Cash and cash equivalent comprises of :				
Cash in hand		1.96		2.04
Balance with banks		-		-
Total		1.96		2.04

Notes:

1. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
2. Figures in bracket indicate cash outgo.
3. Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director & CEO
DIN : 00077026



Place : Mumbai
Date: November 11, 2022